Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

Kerry Rogers, MD

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
Printer Printing...